Phase 2 N=27 The Reinforcing Mechanisms of Smoking in Adult ADHD
ADHD
Primary: The Effects of ADHD Medication Versus Placebo on Cotinine Levels — 180.7; 274.0 ng/ml — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=253 Study of Oral PG-116800 Following a Heart Attack
Myocardial Infarction · Heart Failure · Heart Enlargement
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi in mL/m2) at Day 90 Post Myocardial Infarction (MI) — 5.48; 5.09 mL/m2 — p=0.4239
Phase 2 N=1,220 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Phase 2 N=127 Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
Breast Neoplasms
Primary: Percent of Participants With Grade 3/4 Clinical Congestive Heart Failure (CHF) — 4.3; 0 Percentage of Participants
Phase 2 N=82 Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Multiple Sclerosis
Primary: The Occurrence of ≥ 3 New T2 Lesions With or Without Gd+ Enhancement or Clinical Exacerbation Through 12 Months. — 26; 18 Participants — p=0.929
Phase 2 N=479 Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
West Nile Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine — 5.00; 5.76; 5.06; 5.22 Titers
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
Phase 2 N=491 Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 12 — 0.28; -0.46; -0.52 percent — p=<0.0001
Phase 2 N=94 A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery
Coronary Artery Disease · Heart Valve Disease
Primary: Amount of Postoperative Bleeding — 868.9; 1467.6 mL
Phase 2 N=24 Randomized Crossover Study of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants
Infant, Preterm
Primary: Peak Inspiratory Pressure — 13.45; 12.45 cmH2O — p=0.043
Phase 2 N=222 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1 — 0.32; 0.30; 0.18; 0.02 Number on a scale (score)
Phase 2 N=300 A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
Influenza
Primary: Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine. — 40.5; 28.8; 36.4; 41.4 1/dilution…
Phase 2 N=358 Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
Seizures
Primary: Length of Seizure After Study Medication Administration — 3.0; 4.3 Minutes
Phase 2 N=7 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
Glioma
Primary: Progression-free Survival
Phase 2 N=102 A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Disease, Hodgkin
Primary: Objective Response Rate by Independent Review Group — 75 percent of participants